Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection

• Functional Assessment of HIV Infection (Other): Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
• Patient Satisfaction Questionnaire (Other): Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
• Symptom Distress Module (Other): Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
• Patient Health Questionnaire (Other): Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
• Internalized Stigma of AIDS Tool (Other): Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
• Medication adherence visual analogue scale (Other): Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.

Primary outcomes

• Percentage of virally suppressed PLHIV reporting different HRQoL scores [Up to 1 Week]: Evaluation of HRQoL will be conducted using scores achieved by Functional Assessment of HIV Infection (FAHI). QoL assessment will include physical well-being, social well-being, emotional well-being, functional and global well-being, and cognitive functioning

Secondary outcomes

• Percentage of virally suppressed PLHIV reporting different satisfaction with care scores [Up to 1 Week]: Evaluation of burden will include stigma, stigma, depression, and work productivity. The descriptive analysis will be assessed using Patient Satisfaction Questionnaire (PSQ)-18, Patient Health Questionnaire (PHQ)-2, and ISAT scores
• Percent difference in HRQoL scores among subject subgroups [Up to 1 Week]: Subject subgroups are defined in terms of the following socio-demographic, clinical, and biomedical factors: a. Age: older versus. younger (i.e., < 50 years old and over 50 years old) b. Gender (men / women / transgender) c. Race / ethnicity d. Sexual orientation (straight / gay / bisexual) e. Level of income f. Type of Insurance g. Apple (iPhone operating system) versus Android users h. Treatment regimen (e.g., number of pills per day, frequency of medication, single treatment regimen (STR) versus multiple treatment regimen (MTR) i. Diagnosis time / stage at which diagnosis was received (i.e. prompt vs. late diagnosis, time since diagnosis) j. Absence or presence (and number) of comorbidities k. Severity of symptoms (as assessed by the Symptom Distress Module patient reported outcome (PRO) instrument) l. Achievement of viral suppression.
• Percentage of subjects reporting different HRQoL scores and relationship with satisfaction with care [Up to 1 Week]: Statistical correlation of reported QoL scores (FAHI) and satisfaction with care scores (PHQ-18) will be analyzed.
• Percentage of subjects reporting diffferent HRQoL and medication adherence [Up to 1 Week]: Statistical correlation between QoL scores (FAHI) and adherence scores (adherence VAS) will be analyzed.

Sex: All, ages: 21 Years to any

Inclusion Criteria:

* >= 21 years old
* Language:Read and Understand English / Spanish
* Positive diagnosis of HIV infection by a healthcare provider (self-reported)
* Possesses a smartphone that has internet access

Exclusion Criteria:

* Not Applicable

• GSK Clinical Trials, Study director, ViiV Healthcare